The US Food and Drug Administration (FDA) has accepted for review GSK’s Biologics License Application for depemokimab.
Pharmaceutical majors AstraZeneca and GSK have partnered with competitor Takeda and nine suppliers to accelerate the adoption ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback